Perrigo (PRGO) Q1 2026 Earnings Transcript

Perrigo reported first-quarter CORE net sales down 8.3% and All In net sales down 7.2%, but adjusted CORE EPS of $0.40 came in above internal expectations and management reaffirmed full-year 2026 guidance. The company recorded a $331 million non-cash goodwill impairment and completed the Dermacosmetics divestiture for about EUR 306 million, which will support debt reduction. Operational enhancement savings exceeded $7 million in the quarter, with full-year savings still targeted at $60 million to $80 million, while market share gains in U.S. store brand OTC and Europe partially offset category softness.

Analysis

The setup is less about a clean demand recovery and more about a second-half operating leverage inflection. Perrigo’s near-term data say the core issue is not structural brand erosion but a temporary mismatch between retailer inventory and soft seasonal incidence; that matters because once destocking normalizes, incremental sales should drop through at a higher margin given the cost program already underway. The market is likely underappreciating how much of the earnings bridge is self-help rather than category beta.

The more important second-order effect is competitive: Perrigo is using scale, e-commerce execution, and retailer demand-generation to pull shelf share away from both branded OTC players and smaller private-label suppliers. That is especially visible in categories where the consumer is trading down or shopping digitally, because the retailer’s algorithmic search and merchandising becomes a distribution gatekeeper; if Perrigo improves digital conversion, it can compound share gains without requiring category growth. Infant Formula is a separate overhang, but the strategic review plus asset sale lowers the probability of a balance-sheet event and increases optionality on a cleaner exit or partnership.

The key risk is that management’s “transitory” framing proves too optimistic if cough/cold incidence stays weak into fall or if Europe’s consumer backdrop deteriorates further. In that case, the company has earnings protection but not enough to prevent another reset in the market’s willingness to pay for the back-half story. The other tail risk is that pricing action invites retailer resistance just as share momentum is improving, which could blunt the very volume gains they need to monetize.

Contrarian view: the market may be focusing too much on low-quality headline revenue decline and not enough on the mix of share gains, debt reduction, and a cleaner portfolio. If the second half merely normalizes rather than recovers strongly, the stock can still rerate because 2026 becomes a trough-margin year with visible 2027 cost upside.

Key Decisions for Investors

• Long PRGO into the next 6-12 weeks on any pullback: the setup is for a second-half earnings inflection plus balance-sheet improvement; target a 15-20% re-rating if management executes and category demand stabilizes.
• Buy PRGO Jan-2027 calls or a call spread: risk/reward favors upside convexity because the stock’s multiple is more sensitive to confidence in 2027 margin recovery than to another quarter of weak top-line prints.
• Pair trade: long PRGO / short a basket of branded OTC exposure over 3-6 months if you expect private-label share gains and retailer trade-down to continue; PRGO has self-help, while branded peers have less pricing power in a value-seeking consumer environment.
• Avoid chasing into earnings revisions until there is evidence of inventory normalization: if fall cough/cold remains soft, the shares can fade on any disappointment even with steady execution, so wait for channel checks or a post-quarter inflection.
• Consider a small short-dated put hedge if already long: downside is tied to a broken second-half thesis, and the most likely catalyst for that is another destocking/seasonality disappointment rather than a balance-sheet problem.